Drugs / Methazolamide
Methazolamide
also known as
L-584601 · Metazolamida · Methenamide · Neptazane · Neptazaneat · NSC-758426 · VVP-808
Small molecule targets CA1, CA2, CA4, CA7 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | NEPTAZANE | — | 1991-11-25 | fda.gov ↗ |
| Approved | US (FDA) | NEPTAZANE | — | 1959-01-26 | fda.gov ↗ |
Trials 7
19581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06312800 | Mar 2016 → Jun 2017 | essential tremor | Henry Ford Health System | Withdrawn | No outcome recorded |
| Phase 2 | NCT00257829 | Jul 2004 → Sep 2006 | cervical cancer | University of California, Irvine | Withdrawn | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT02390284 | Sep 2015 → Oct 2024 | glaucoma | University of Miami | Terminated | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05575180 | Aug 2023 → Feb 2024 | altitude sickness | University of Waterloo | Completed | No outcome recorded |
| Phase 4 | NCT02758470 | Nov 2016 → Jun 2017 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT02760121 | May → Aug 2016 | altitude sickness, pulmonary hypertension | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT02463357 | Aug 2015 → Sep 2016 | altitude sickness | University of Colorado, Denver | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01587027 Comparator | Dec 2011 → Feb 2012 | altitude sickness | Poudre Valley Health System | Completed | No outcome recorded |
| Phase 1/2 | NCT01702025 Comparator | Jun → Dec 2012 | — | Colorado State University | Completed | No outcome recorded |
| Phase 4 | NCT05498103 Comparator | Feb → Sep 2023 overdue | open-angle glaucoma | University of Colorado, Denver | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-03-12 | Perrigo Company | Perrigo Announces Launch Of Generic Version Of Neptazane™ (Methazolamide) Tablets perrigo.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methazolamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02463357 ↗ |
| Known as | L-584601 | ChEMBL registry synonym — accepted as the source's own label CHEMBL19 ↗ |
| Known as | Metazolamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL19 ↗ |
| Known as | Methenamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL19 ↗ |
| Known as | Neptazane | ChEMBL registry synonym — accepted as the source's own label CHEMBL19 ↗ |
| Known as | Neptazaneat | ChEMBL registry synonym — accepted as the source's own label CHEMBL19 ↗ |
| Known as | NSC-758426 | ChEMBL registry synonym — accepted as the source's own label CHEMBL19 ↗ |
| Known as | VVP-808 | ChEMBL registry synonym — accepted as the source's own label CHEMBL19 ↗ |
| Action | Inhibit | “Carbonic anhydrase VII inhibitor” CHEMBL19 ↗4“Carbonic anhydrase IV inhibitor” CHEMBL19 ↗ “Carbonic anhydrase II inhibitor” CHEMBL19 ↗ “a carbonic anhydrase inhibitor” PMID 26680684 ↗ Dec 2015 “Carbonic anhydrase I inhibitor” CHEMBL19 ↗ |
| Modality | Small molecule | — CHEMBL19 ↗ |
| Route | Oral | “Methazolamide 250mg orally” NCT01587027 ↗ |
| Target | CA1 | “Carbonic anhydrase I inhibitor” CHEMBL19 ↗ |
| Target | CA2 | “Carbonic anhydrase II inhibitor” CHEMBL19 ↗ |
| Target | CA4 | “Carbonic anhydrase IV inhibitor” CHEMBL19 ↗ |
| Target | CA7 | “Carbonic anhydrase VII inhibitor” CHEMBL19 ↗ |